At Teva, we believe that the rising incidence of chronic diseases demands a future with biosimilars.1
Because a sustainable solution is needed to address the rising pressure on healthcare systems to improve patient outcomes worldwide, Teva is prepared to deliver a robust portfolio of biosimilars across key therapeutic areas.
With drug costs rapidly escalating, there is a need for broader adoption of biosimilars—a need that Teva is approaching with meaningful cost-savings options.2,3
With the world’s largest fully integrated supply and delivery network, Teva is ready to reliably supply more than 20 quality biosimilar products on a global scale.
Because of a global recognition to improve regulatory approval processes, Teva works with health authorities and trade associations around the world to create policy environments beneficial to increasing patient access to biosimilars.4,5
In the ever-evolving biosimilar marketplace, it is anticipated that biosimilar acceptance, uptake, and use
will continue to increase, with market growth expected to reach more than $121 billion globally by 2033.6
Biosimilars are cost-effective medicines; their availability is critical for patient access and savings for the healthcare system.7
In the European Union, biosimilars are estimated to have saved more than €30 billion on catalog prices as of 2022.8
In the United States, biosimilars are expected to save $181 billion by 2028 as their use becomes more widespread.9
Global savings from biosimilars are estimated to exceed $290 billion in cumulative spending through 2027.10
Biosimilars may open new opportunities for patient care.
As of 2024, patients have collectively used biosimilars for almost 2.7 billion total days of therapy, with the availability of different biosimilars resulting in 495 million additional patient days.11
There is no one-size-fits-all approach to biosimilar product development.
The goal of a biosimilar development program is to use a totality of evidence approach to demonstrate biosimilarity to the reference product, rather than independently establish the safety and efficacy of the proposed biosimilar.12
Advanced analytics—in which Teva has developed significant expertise—play a crucial role in the totality of evidence approach, validating the efficacy, safety, and immunogenicity of the biosimilar.13
A high degree of analytical similarity provides scientific justification for reduced regulatory requirements, further facilitating the overall abbreviated approval process for biosimilars.4
Comparative clinical studies14
Comparative pharmacology (PK/PD)14
Comparative nonclinical evaluations14
Comparative analytical analysis14
PD=pharmacodynamics; PK=pharmacokinetics.
Having spent decades delivering affordable medicines as the world’s largest generics manufacturer, Teva has made it a global priority to offer competitively priced, easily accessible biosimilars.
Are you sure you want to leave? There’s more informative content to discover.